Asia Myelodysplastic Syndrome (MDS) Registry

Condition(s) studied

Investigational drug(s) / intervention(s)

Prescribed treatments for myelodysplastic syndromes (MDS): According to the product label

Study summary

The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.

Eligibility

Primary outcome measure(s)

• Participant age — Baseline
• Participant sex — Baseline
• Participant race — Baseline
• Participant weight — Baseline
• Participant height — Baseline
• Participant body mass index (BMI) — Baseline
• Participant smoking status — Baseline
• Participant drinking status — Baseline
• Family history of MDS or other hematopoietic cancers — Baseline
• Participant myelodysplastic syndromes diagnosis information — Baseline
• Participant Eastern Cooperative Oncology Group (ECOG) Performance status at diagnosis — Baseline
• Participant comorbidities at diagnosis — Baseline
• Participant Charlson comorbidity index (CCI) score at diagnosis — Baseline
• Prior clinical diagnosis of other cancers — Baseline
• Prior clinical diagnosis of hematological diseases — Baseline
• Anemia status at diagnosis — Bseline
• Thrombocytopenia status at diagnosis — Baseline
• Neutropenia status at diagnosis — Baseline
• Iron overload status at diagnosis — Baseline
• Red blood cell (RBC) transfusion dependence status at diagnosis — Baseline
• International Prognostic Scoring System (IPSS) score at diagnosis — Baseline
• Revised International Prognostic Scoring System (IPSS-R) score at diagnosis — Baseline
• Molecular International Prognostic Scoring System (IPSS-M) score at diagnosis — Baseline
• Bone marrow aspirate results — Baseline and up to 2-years
• Presence of dysplasia — Baseline and up to 2-years
• Cytogenetic test results — Baseline and up to 2-years
• Mutation test results at diagnosis — Baseline
• Complete blood count test results at diagnosis — Baseline
• Mean corpuscular volume (MCV) — Baseline and up to 2-years
• C-reactive protein (CRP) — Baseline and up to 2-years
• Serum ferritin (SF) level — Baseline and up to 2-years
• Serum erythropoietin levels — Baseline and up to 2-years
• Lactate dehydrogenase (LDH) — Baseline and up to 2-years

Trial sites (3)

More Bristol-Myers Squibb trials in Singapore